Literature DB >> 7736574

Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation.

T Miyazaki1, Z J Liu, A Kawahara, Y Minami, K Yamada, Y Tsujimoto, E L Barsoumian, R M Permutter, T Taniguchi.   

Abstract

Two interleukin-2 receptor-dependent signaling pathways have thus far been identified: the c-fos/c-jun induction pathway mediated by src family protein-tyrosine kinases and the c-myc induction pathway. Here, we provide evidence for the existence of a third, rapamycin-sensitive pathway, which results in the induction of another proto-oncogene, bcl-2. In the hematopoietic cell line BAF-B03, the expression of any two of lckF505 (an active form of p56lck), Bcl-2, or c-Myc is sufficient to promote transit of the cell cycle, regardless of the activation state of the third pathway. We also provide evidence that epidermal growth factor receptor signaling may act through the same pathway that involves p56lck. These studies demonstrate a novel approach to dissecting signaling pathways regulating cellular proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7736574     DOI: 10.1016/0092-8674(95)90332-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  84 in total

1.  Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization.

Authors:  F Romero; C Martínez-A; J Camonis; A Rebollo
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1.

Authors:  Brian M Iritani; Jeffrey Delrow; Carla Grandori; Ivan Gomez; Meredith Klacking; Leni Sue Carlos; Robert N Eisenman
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

4.  Ligation of CD8 leads to apoptosis of thymocytes that have not undergone positive selection.

Authors:  Kristie M Grebe; Raedun L Clarke; Terry A Potter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-01       Impact factor: 11.205

5.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

6.  Isozymes of nuclear protein tyrosine kinase during chemical induced hepatocarcinogenesis in rats.

Authors:  H Zhang; Y Huang; H L Chen
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

7.  The protooncogene MYC can break B cell tolerance.

Authors:  Yosef Refaeli; Kenneth A Field; Brian C Turner; Andreas Trumpp; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

8.  Age-related T-cell cytokine profile parallels corneal disease severity in Sjogren's syndrome-like keratoconjunctivitis sicca in CD25KO mice.

Authors:  Cintia S De Paiva; Cindy S Hwang; John D Pitcher; Solherny B Pangelinan; Ehsan Rahimy; Wei Chen; Kyung-Chul Yoon; William J Farley; Jerry Y Niederkorn; Michael E Stern; De-Quan Li; Stephen C Pflugfelder
Journal:  Rheumatology (Oxford)       Date:  2009-12-09       Impact factor: 7.580

9.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

Review 10.  Recent advances in the understanding of interleukin-2 signal transduction.

Authors:  F Gesbert; M Delespine-Carmagnat; J Bertoglio
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.